SCHEMBL3524810

SCHEMBL3524810

CCOC(=O)c1cn(C2CCCCC2)c2nc(Nc3ccc(C4CCN(C(=O)CN(C)C)CC4)cc3)ncc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 12/20 0.63
CDK4 P11802 6/20 0.45
CCND1 P24385 4/20 0.45
CCNA2 P20248 3/20 0.45
CDK2 P24941 3/20 0.45
FGFR1 P11362 2/20 0.45
FGFR2 P21802 2/20 0.45
FGFR4 P22455 2/20 0.45
FGFR3 P22607 2/20 0.45
CCND2 P30279 2/20 0.45
CCND3 P30281 2/20 0.45
CCNA1 P78396 1/20 0.45
INSR P06213 2/20 0.44
KIT P10721 2/20 0.44
SRC P12931 2/20 0.44
FLT3 P36888 2/20 0.44
NTRK1 P04629 1/20 0.44
PDGFRB P09619 1/20 0.44
BTK Q06187 1/20 0.41
CDK6 Q00534 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530725 0.90 CSF1R (0.66) CSF1RCDK4INSRKITSRC
SCHEMBL4572719 0.90 CSF1R (0.77) CSF1RCDK4CCND1CCNA2CDK2
SCHEMBL14567625 0.89 CSF1R (0.67) CSF1RCDK4INSRKITSRC
SCHEMBL3524814 0.86 CSF1R (0.58) CSF1RINSRKITSRCFLT3
SCHEMBL3527782 0.85 CSF1R (0.57) CSF1RCDK4CCND1CCNA2CDK2
SCHEMBL3527122 0.83 CSF1R (0.71) CSF1RINSRKITSRCFLT3
SCHEMBL4574257 0.82 CSF1R (0.74) CSF1RCDK4CCND1CCNA2CDK2
SCHEMBL4574276 0.81 CSF1R (0.84) CSF1RINSRKITSRCFLT3
SCHEMBL4583669 0.81 CSF1R (0.72) CSF1RCDK4CCND1CCNA2CDK2
SCHEMBL3530132 0.81 CSF1R (0.79) CSF1RCDK4CCND1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 427/4885CDK4 212/4885CCND1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.